pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering